How to buy Novavax shares
Own Novavax shares in just a few minutes.
Novavax, Inc is a biotechnology business with stocks listed in the US. Novavax shares (NVAX) are listed on the NASDAQ and all prices are listed in US Dollars.
How to buy shares in Novavax
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Novavax. Find the share by name or ticker symbol: NVAX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Novavax reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Novavax, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Novavax. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Novavax share priceUse our graph to track the performance of NVAX stocks over time.
Novavax shares at a glance
|52-week range||USD$3.54 - USD$189.4|
|50-day moving average||USD$122.7803|
|200-day moving average||USD$70.8592|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-8.597|
Standard brokerage - US shares
Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.
- $0 brokerage for US stocks
- Trades starting from $50
- Fractional shares
- Copy top traders
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Novavax stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Revenue TTM||US$50.2 million|
|Gross profit TTM||US$-95,180,000|
|Return on assets TTM||-10.32%|
|Return on equity TTM||-93.79%|
|Market capitalisation||US$6.3 billion|
TTM: trailing 12 months
Shorting Novavax shares
There are currently 8.5 million Novavax shares held short by investors – that's known as Novavax's "short interest". This figure is 6% up from 8.0 million last month.
There are a few different ways that this level of interest in shorting Novavax shares can be evaluated.
Novavax's "short interest ratio" (SIR)
Novavax's "short interest ratio" (SIR) is the quantity of Novavax shares currently shorted divided by the average quantity of Novavax shares traded daily (recently around 8.7 million). Novavax's SIR currently stands at 0.98. In other words for every 100,000 Novavax shares traded daily on the market, roughly 980 shares are currently held short.
However Novavax's short interest can also be evaluated against the total number of Novavax shares, or, against the total number of tradable Novavax shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novavax's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Novavax shares in existence, roughly 140 shares are currently held short) or 0.1389% of the tradable shares (for every 100,000 tradable Novavax shares, roughly 139 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novavax.
Find out more about how you can short Novavax stock.
Novavax share dividends
We're not expecting Novavax to pay a dividend over the next 12 months.
Have Novavax's shares ever split?
Novavax's shares were split on a 1:20 basis on 9 May 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novavax shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Novavax shares which in turn could have impacted Novavax's share price.
Novavax share price volatility
Over the last 12 months, Novavax's shares have ranged in value from as little as US$3.54 up to US$189.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novavax's is 1.5028. This would suggest that Novavax's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Frequently asked questions
Ask an Expert